Highest-materiality recent filing
Begins trading on OTCQX effective February 12, 2024 under symbol SFES.
Safeguard Scientifics files Form 25 to voluntarily delist from Nasdaq, expects suspension Feb 12
Filed Form 25 with SEC on Feb 2, 2024 to voluntarily delist common stock from Nasdaq.
Safeguard Scientifics to voluntarily delist from Nasdaq on Feb 2, 2024; plans to deregister
Filed notice to delist common stock from Nasdaq via Form 25 on February 2, 2024.
Safeguard Scientifics sets Jan 12 for stock splits to enable going dark; names Mark Dow CEO/CFO
1-for-100 reverse split then 100-for-1 forward split effective Jan 12; trading on Nasdaq post-split Jan 16.
Safeguard Scientifics to delist from Nasdaq after 1-for-100 reverse split; special dividend $0.35
Shareholders approved reverse stock split 1-for-100 followed by forward split 100-for-1 to reduce record holders below 300.
Special cash dividend of $0.35 per share, payable Dec 28 to holders of record Dec 19.
Safeguard Scientifics Q3 net income $0.9M, vs loss $3.2M; cash $15.7M
Q3 net income $0.9M ($0.06 diluted EPS) vs net loss $3.2M ($0.19 loss) in Q3 2022.
Safeguard Scientifics board approves plan to go private via stock splits, delist from Nasdaq
Reverse stock split (1:50 to 1:100) followed by forward split; small holders cashed out at $1.65/share.
Safeguard Scientifics Q2 2023 net loss of $2.9M; six portfolio co. revenue up 12.8%
Net loss Q2 2023 of $2.9M ($0.18/sh) vs net income $0.5M ($0.03/sh) in Q2 2022.
Safeguard Scientifics shareholders approve all four proposals at 2023 annual meeting
Elected directors DeMont, Glass, Manko, Michelson with >7.3M votes each.
Safeguard Scientifics Q1 net loss narrows to $3.5M; in advanced deal talks
Net loss $3.5M ($0.22/sh) vs $6.7M loss in Q1 2022; cash $18.8M.
Safeguard reports no direct SVB exposure; seven portfolio cos have deposits, $9M undrawn loans
Safeguard has no banking relationship with Silicon Valley Bank.
Safeguard Scientifics posts FY2022 net loss of $14.3M vs net income of $27.0M in 2021
Net loss Q4 2022 $4.9M ($0.30/share) vs loss $8.6M ($0.51) in Q4 2021; FY2022 net loss $14.3M ($0.87) vs net income $27.0M ($1.36) in FY2021.
Safeguard completes $3M share repurchase program; reports $19.3M cash at year-end
Repurchased 736,577 shares at avg $4.09/share under $3M plan announced March 2022.
CEO Eric Salzman enters new employment agreement through Dec 31, 2023; base salary $500K
Base salary of $500,000 per year; term runs Jan 1, 2023 to Dec 31, 2023.
Safeguard Scientifics Q3 2022 net loss $3.2M vs prior-year net income $18.3M
Received $5.3M initial cash proceeds from Lumesis acquisition, recording a gain of $4.7M.
Safeguard Scientifics transfers listing from NYSE to Nasdaq Capital Market, effective Oct 26
Voluntary withdrawal from NYSE; trading ends Oct 25, begins on Nasdaq Oct 26, 2022.
Safeguard Scientifics exits Lumesis via sale to SOLVE Advisors for $5.3M initial cash
Safeguard received $5.3M initial cash proceeds from sale of Lumesis stake to SOLVE Advisors.
Net income of $0.5M ($0.03/diluted EPS) vs net loss of $0.3M ($0.02 loss/share) in Q2 2021.
Shareholders elect two new directors, approve executive compensation and auditor
Ross D. DeMont and Beth S. Michelson elected to board; DeMont to chair Compensation Committee.
Safeguard Scientifics Q1 net loss $6.7M; strategic review with Houlihan Lokey continues
Net loss $6.7M ($0.40 per share) vs net income $17.6M ($0.84 per share) in Q1 2021.
Safeguard Scientifics authorizes $3M share repurchase, replacing prior $6M plan
New $3M buyback replaces $6M plan announced May 2021; expects completion by end of 2022.
Safeguard Scientifics reports $60.8M cash proceeds from 2021 exits; initiates strategic review
Repurchased 4.5M shares in 2021, including 4.3M via Dutch auction at $9.06 per share.
Annual base salary of $500,000; term ends December 31, 2022.
Safeguard posts Q3 net income of $18.3M ($0.88 per share); completes $38.7M self-tender
Repurchased 4.3M shares for $38.7M via modified Dutch auction self-tender completed Oct 7, 2021.
Completed sale of Flashtalking interest for ~$44.8M cash; up to $0.8M additional from escrow over 24 months.
Transcript of August 12, 2021 earnings call furnished as Exhibit 99.1; only introductory remarks provided.
Safeguard Scientifics Q2 net loss narrows to $0.3M; expects $43M from Flashtalking sale
Net loss of $0.3M ($0.02 per share) vs loss of $9.9M ($0.48) in Q2 2020; improvement driven by $9.2M in gains.
Safeguard Scientifics announces Flashtalking acquisition by Mediaocean; expects $43M cash
Flashtalking, a Safeguard portfolio company, signed definitive agreement to be acquired by Mediaocean.
the Board appointed Mark Dow of Rock Creek as the Company’s Chief Executive Officer, Chief Financial Officer and Secretary effective as of January 1, 2024.
Messrs. Salzman and Herndon will no longer serve as the Company’s executive officers as of December 31, 2023
Messrs. Salzman and Herndon will no longer serve as the Company’s executive officers as of December 31, 2023
Ross D. DeMont and Beth S. Michelson were elected as directors of the Company
Ross D. DeMont and Beth S. Michelson were elected as directors of the Company
Max materiality 0.85 · Median 0.60 · Most common event earnings